Antifibrotics in systemic sclerosis

Area of Science:

• Rheumatology and Pulmonology
• Fibrotic diseases
• Autoimmune disorders

Background:

• Systemic sclerosis (SSc) is a rare, multi-organ autoimmune disease characterized by fibrosis, vascular damage, and inflammation.
• High morbidity and mortality associated with SSc present significant management challenges due to disease heterogeneity and limited clinical trials.
• Current treatments, including immunosuppressants, offer modest benefits, highlighting the need for more effective antifibrotic strategies.

Purpose of the Study:

• To review current and emerging antifibrotic therapies for Systemic Sclerosis (SSc).
• To summarize evidence on the efficacy and safety of antifibrotic agents in SSc patients.
• To address the unmet need for personalized treatment strategies in SSc management.

Main Methods:

• Literature review of clinical trials and studies on antifibrotic therapies in Systemic Sclerosis.
• Analysis of data on nintedanib's efficacy in SSc-associated interstitial lung disease (ILD).
• Evaluation of emerging antifibrotic agents and their potential in SSc treatment.

Main Results:

• Nintedanib, a tyrosine kinase inhibitor, shows demonstrated safety and efficacy in treating ILD associated with SSc.
• Several other antifibrotic agents are under investigation with promising preliminary results.
• Evidence suggests a growing therapeutic landscape for antifibrotic interventions in SSc.

Conclusions:

• Antifibrotic therapies, including nintedanib, represent a significant advancement in managing Systemic Sclerosis, particularly for lung manifestations.
• Further research is needed to define optimal patient selection, timing, and choice of antifibrotic agents for SSc.
• Personalized therapeutic approaches are crucial for improving outcomes in SSc patients.